Diabetes drug may significantly reduce risk of death

08/7/2008 | NYTimes.com

Results from the Accord clinical trial suggest the injectable drug Byetta may reduce the risk of death among people with Type 2 diabetes by as much as 75%, compared with patients on other diabetes medications. There is debate about the validity of the findings, however, and Eli Lilly and Co. and Amylin Pharmaceuticals, which market Byetta, have not publicized them.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations